|Security||RGNX / REGENXBIO Inc. (75901B107)|
|Industry||Biological Products, Except Diagnostic Substances (Biotech)|
|Common Shares Outstanding||31,655,093 shares (as of 2017-12-31)|
Stock Insider Trading (from SEC Form 4)
REGENXBIO Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
RGNX / REGENXBIO Inc. insiders include DEERFIELD PARTNERS, L.P., and Deerfield Mgmt L.P., Vasista Vittal, KARABELAS ARGERIS N, Deerfield Mgmt III, L.P., Danos Olivier, ENGLEMAN EDGAR Simpson Curran, Fox Allan M., Flynn James E, FMR LLC / Fidelity Management & Research, Yoo Stephen, DEERFIELD MANAGEMENT CO, Deerfield International Master Fund, L.P., Ali Faraz, BESHAR LUKE M, Deerfield Private Design Fund III, L.P., Christmas Patrick J., Mills Kenneth T., Abdun-Nabi Daniel, Tasse Daniel, Samuels Camille D, HAYDEN DONALD J JR, STUMP DAVID C, .
HAYDEN DONALD J JR
Christmas Patrick J.
Mills Kenneth T.
BESHAR LUKE M
STUMP DAVID C
Fox Allan M.
KARABELAS ARGERIS N
Samuels Camille D
FMR LLC / Fidelity Management & Research
DEERFIELD MANAGEMENT CO
Flynn James E
Deerfield Mgmt L.P.
Deerfield Mgmt III, L.P.
Deerfield Private Design Fund III, L.P.
Deerfield International Master Fund, L.P.
DEERFIELD PARTNERS, L.P.
Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.
|4||HAYDEN DONALD J JR||S||X||D||50.06||-9,847||0|
|4||HAYDEN DONALD J JR||M||X||D||0.85||9,847||9,847|
|4||HAYDEN DONALD J JR||S||X||D||50.04||-5,153||0|
|4||HAYDEN DONALD J JR||M||X||D||0.85||5,153||5,153|
|4||HAYDEN DONALD J JR||S||X||D||45.00||-15,000||0|
|4||HAYDEN DONALD J JR||M||X||D||0.85||15,000||15,000|
|4||Christmas Patrick J.||M||D||12.10||15,000||16,141|
|4||Christmas Patrick J.||S||X||D||44.00||-10,000||1,141||50,204|
|4||Christmas Patrick J.||S||X||D||42.00||-5,000||11,141||467,922|
|4||Christmas Patrick J.||M||X||D||12.10||15,000||16,141|
|4||Mills Kenneth T.||S||X||D||39.93||-900||218,530||8,725,903|
|4||Mills Kenneth T.||S||X||D||39.48||-9,100||219,430||8,663,096|
|4||Christmas Patrick J.||S||X||D||39.00||-10,000||1,141||44,499|
|4||Christmas Patrick J.||M||X||D||12.10||10,000||11,141|
|4||Christmas Patrick J.||S||X||D||34.00||-10,000||1,141||38,794|
|4||Christmas Patrick J.||M||X||D||12.10||10,000||11,141|
|4||Mills Kenneth T.||S||X||D||29.55||-10,000||228,530||6,753,062|
|4||Mills Kenneth T.||S||X||D||26.56||-10,000||238,530||6,335,357|
|4||Mills Kenneth T.||S||X||D||27.33||-10,000||248,530||6,792,325|
|4||Mills Kenneth T.||M||D||0.85||150,000||258,530|
|4||Christmas Patrick J.||A||D||17.425||486||1,141|
|4||Christmas Patrick J.||A||D||15.725||655||655|
|4||Mills Kenneth T.||S||X||D||31.75||-10,000||108,530||3,445,828|
|4||Mills Kenneth T.||S||X||D||27.71||-10,000||118,530||3,284,466|
|4||Mills Kenneth T.||M||D||0.85||30,000||128,530|
|4||Mills Kenneth T.||S||X||D||33.03||-200||98,530||3,254,446|
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
Related News Stories
The current quarterly cash burn remains modest leaving most of the group with enough capital to operate through 3 to 5 years. (96-3)
Good day, ladies and gentlemen, and welcome to the first quarter 2018 REGENXBIO earnings conference call. [Operator Instructions] (5-0)
Today's fund in the spotlight, Ra CapitalManagement, has the best performance of the funds we´ve looked at so far. (190-2)
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious. (5-0)
Perhaps the biggest winner of the Novartis (NVS) buyout of AveXis (AVXS) for $8.7 billion was REGENXBIO (RGNX). REGENXBIO licenses out its adeno-associated virus (AAV) technology to other gene editing companies, including AveXis. This acquisition immediately benefited AveXis shareholders, but the true value may lie with REGENXBIO. REGENXBIO’s technology platform is the backbone of everything AveXis does and Novartis just gave a huge vote of confidence to that platform. (12-1)
as of ET